Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling Pathway by Cizkova, Magdalena et al.
Gene Expression Profiling Reveals New Aspects of
PIK3CA Mutation in ERalpha-Positive Breast Cancer:
Major Implication of the Wnt Signaling Pathway
Magdalena Cizkova
1,2.,G e ´raldine Cizeron-Clairac
1., Sophie Vacher
1, Aure ´lie Susini
1, Catherine
Andrieu
1, Rosette Lidereau
1, Ivan Bie `che
1*
1Laboratoire d’Oncoge ´ne ´tique, Institut National de la Sante ´ et de la Recherche, U745, Institut Curie/Ho ˆpital Rene ´ Huguenin, St-Cloud, France, 2Laboratory of
Experimental Medicine, Department of Paediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
Abstract
Background: The PI3K/AKT pathway plays a pivotal role in breast cancer development and maintenance. PIK3CA, encoding
the PI3K catalytic subunit, is the oncogene exhibiting a high frequency of gain-of-function mutations leading to PI3K/AKT
pathway activation in breast cancer. PIK3CA mutations have been observed in 30% to 40% of ERa-positive breast tumors.
However the physiopathological role of PIK3CA mutations in breast tumorigenesis remains largely unclear.
Methodology/Principal Findings: To identify relevant downstream target genes and signaling activated by aberrant PI3K/
AKT pathway in breast tumors, we first analyzed gene expression with a pangenomic oligonucleotide microarray in a series
of 43 ERa-positive tumors with and without PIK3CA mutations. Genes of interest were then investigated in 249 ERa-positive
breast tumors by real-time quantitative RT-PCR. A robust collection of 19 genes was found to be differently expressed in
PIK3CA-mutated tumors. PIK3CA mutations were associated with over-expression of several genes involved in the Wnt
signaling pathway (WNT5A, TCF7L2, MSX2, TNFRSF11B), regulation of gene transcription (SEC14L2, MSX2, TFAP2B, NRIP3) and
metal ion binding (CYP4Z1, CYP4Z2P, SLC40A1, LTF, LIMCH1).
Conclusion/Significance: This new gene set should help to understand the behavior of PIK3CA-mutated cancers and
detailed knowledge of Wnt signaling activation could lead to novel therapeutic strategies.
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Introduction
Deregulation of the phosphatidylinositol 3-kinase (PI3K)
signaling pathway is frequent in human cancers. Activation of
PI3K, which catalyzes inositol lipid phosphorylation to produce
phosphatidylinositol-3,4,5-trisphosphate, is one of the most
important downstream molecular events following tyrosine kinase
receptor activation. Phosphatidylinositol-3,4,5-trisphosphate acti-
vates the serine/threonine kinase AKT, which in turn regulates
several signaling pathways controlling cell survival, apoptosis,
proliferation, motility, and adhesion [1]. PI3K is a heterodimeric
enzyme composed of a p110a catalytic subunit encoded by the
PIK3CA gene, and a p85 regulatory subunit encoded by the
PIK3R1 gene [2].
Gain-of-function mutations in PIK3CA have recently been found
in several malignancies, including breast cancer [1,3,4]. PIK3CA is
frequently mutated at ‘‘hotspots’’ in exons 9 and 20, corresponding
to the helical (E542K and E545K) and kinase (H1047R) domains,
respectively. P110a carrying a hotspot mutation has oncogenic
activity, transforming primary fibroblasts in culture, inducing
anchorage-independent cell growth, and causing tumors in
animals [5,6].
After the TP53 suppressor gene, the PIK3CA oncogene is the
most frequently mutated gene in human breast cancers (up to 40%
of breast tumors) [7,8]. Activating somatic mutations of other
oncogenes (EGFR, KRAS, HRAS, NRAF, BRAF and AKT1) involved
in downstream molecular events following tyrosine kinase receptor
activation are frequent in several malignancies but rare in breast
cancer. Several studies suggest that PIK3CA mutations are more
frequent in estrogen receptor alpha (ERa)-positive breast tumors
(30–40%) than in ERa-negative breast tumors (10–20%) [7].
The pathological role of these gain-of-function PIK3CA
mutations in breast tumors, and particularly in ERa-positive
breast tumors, is largely unknown. Better knowledge of PIK3CA
mutation impact requires the identification of downstream target
genes and signaling pathways activated by aberrant PI3K/AKT
signaling. Here, we compared gene expression in PIK3CA-mutated
and PIK3CA wild-type ERa-positive breast tumors, using a
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15647genome-wide microarray and subsequently real-time quantitative
reverse transcriptase-polymerase chain reaction (RT-PCR).
Materials and Methods
Patients and Samples
We analyzed samples of 292 primary unilateral non metastatic
ERa-positive postmenopausal breast tumors excised from women
at Rene ´ Huguenin Hospital (Saint-Cloud, France) from 1978 to
2008. Other characteristics of the patients are listed in Table S1.
Each patient gave written informed consent and this study was
approved by the Local Ethical Committee (Breast Group of Rene ´
Huguenin Hospital). Immediately after surgery the tumor samples
were stored in liquid nitrogen until RNA extraction. The samples
analyzed contained more than 70% of tumor cells. ERa status was
determined at the protein level by using biochemical methods
(Dextran-coated charcoal method until 1988 and enzyme
immunoassay thereafter) and was confirmed at mRNA level by
real-time RT-PCR. Forty-three samples were used as a microarray
and RT-PCR screening set to identify differentially expressed
genes. These genes were then validated in the remaining 249 ERa-
positive tumors by means of RT-PCR. Control samples consisted
of eight specimens of normal breast tissue collected from women
undergoing cosmetic breast surgery or adjacent normal breast
tissue from breast cancer patients.
RNA extraction
Total RNA was extracted from breast tissue by using the acid-
phenol guanidium method, and its quality was determined by
agarose gel electrophoresis and ethidium bromide staining. The
18S and 28S RNA bands were visualized under ultraviolet light.
PIK3CA mutation screening
PIK3CA mutation screening was performed on cDNA fragments
obtained by RT-PCR amplification of exons 9 and 20 and their
flanking exons. Details of the primers and PCR conditions are
available on request. The amplified products were sequenced with
the BigDye Terminator kit on an ABI Prism 3130 automatic DNA
sequencer (Applied Biosystems, Courtabœuf, France). Sequences
thus obtained were compared with the corresponding cDNA
reference sequence (NM_006218).
Microarray analysis
Microarray experiments used Human Genome U133 Plus 2.0
arrays from Affymetrix, containing 54675 probe sets. Gene chips
were hybridized and scanned using standard Affymetrix protocols.
Expression data were obtained as CEL files. BRB ArrayTools
(version 3.6.0 available on http://linus.nci.nih.gov/BRB-Array
Tools.html) were used to import CEL files with Robust Method
Average (RMA) normalization, and to analyze gene expression. A
class comparison based on a univariate t test applied to log-
normalized data was used to identify genes differentially expressed
in breast tumors with and without PIK3CA mutations. Supervised
class prediction analysis was implemented with the Prediction
Analysis for Microarrays (PAM) algorithm to identify genes
required for optimal prediction [9].
The Database for Annotation, Visualization and Integrated
Discovery (DAVID, available on http://david.abcc.ncifcrf.gov/)
was used to interpret the lists of differentially expressed probes and
to identify statistically overrepresented biological function catego-
ries of Gene Ontology (GO) and biological pathways, as defined in
the Kyoto Encyclopedia of Genes and Genomes (KEGG).
In compliance with the Minimun Information About a
Microarray Experiment (MIAME) recommendations, raw data
were deposited in the Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/geo/) under series accession num-
ber GSE22035.
Real-time quantitative RT-PCR
RT-PCR was applied to the selected genes, as well as ERa
(NM_000125), MKI67 (NM_002417), and TBP (NM_003194;
endogenous mRNA control). Primers and PCR conditions are
available on request, and the RT-PCR protocol using the SYBR
Green Master Mix kit on the ABI Prism 7900 Sequence Detection
System (Perkin-Elmer Applied Biosystems, Foster City, CA, USA)
is described in detail elsewhere [10]. The relative mRNA
expression level of each gene, expressed as the N-fold difference
in target gene expression relative to the TBP gene, and termed
‘‘Ntarget’’, was calculated as Ntarget=2
DCt
sample. The value of the
cycle threshold (DCt) of a given sample was determined by
subtracting the average Ct value of the target gene from the
average Ct value of the TBP gene. The Ntarget values of the
samples were subsequently normalized such that the median
Ntarget value of the normal breast samples was 1. The relative
expression of each gene was characterized by the median and
range, and the differences in gene expression between tumors with
and without PIK3CA mutations were analysed for significance with
the non parametric Mann-Whitney U test.
Clustering analysis
Hierarchical clustering analyses of gene expression and samples
were performed using BRB ArrayTools. Classification perfor-
mance was calculated as overall accuracy, defined as the
proportion of correctly classified tumors in each cluster, using
Matthews’ correlation coefficient (MCC) [11]. This parameter was
used to discriminate identical accuracies. The chi-square test was
used to determine the statistical significance of the clustering.
Results
Analysis of differentially expressed genes in 43 ERa-
positive tumors
Overview of transcriptome changes in PIK3CA-mutated
tumors. To identify PIK3CA mutation-related genes,
microarray analysis (Affymetrix U133 Plus 2.0 arrays) was first
applied to 43 ERa-positive breast tumors, of which 14 were
PIK3CA-mutated and 29 were wild-type (Table S1). We found that
6124 probes were differentially expressed between breast tumors
with and without PIK3CA mutations, with P values ,0.05. Of
these, 2538 probes (1630 unique genes) were up-regulated (Table
S2) and 3586 (2672 unique genes) were down-regulated (Table
S3). Only 216 up-regulated probes (153 unique genes) and 28
down-regulated probes (18 unique genes) showed at least a 2-fold
change (FC).
Gene ontology analysis of differentially expressed
genes. To identify families of genes that might have significant
roles related to specific biological or molecular processes, we used
the DAVID database to annotate the 6124 probes and categorize
them by function. As shown in Table 1, these genes were mainly
involved in the regulation of transcription, cell cycling,
proliferation, death, adhesion and cytoskeleton organization, and
also ion binding and transport, and ATP and RNA binding
activity.
The 2672 down-regulated genes were mainly associated with
ATP binding, acetylation and ion transport (Table 1). Among the
down-regulated genes with FC$2, no significantly overrepresent-
ed GO categories appeared.
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transcriptional regulation (17.3%) (biological process) and ion
binding (25.6%) (molecular function) (Table 1). The latter included
the metal ion-binding and zinc ion-binding categories (Table 1).
As shown in Figure 1A, the 216 probes most strongly up-regulated
in PIK3CA-mutated tumors (153 unique genes) belonged mainly to
the ion-binding category (35.5%) but also to categories of
structural molecule activity (including structural cytoskeleton
constituents) (9.3%), transcription regulatory activity (9.3%) and
nucleotide binding (including ATP and GTP binding) (7.5%).
In the ion-binding category, the genes corresponded to genes
encoding metal ion-binding proteins in 95% of cases: 28%
encoding iron ion-binding and 23% with zinc ion-binding proteins
(Figure 1B), pointing to a role of ion-binding proteins, and
especially iron ion-binding proteins, in breast cancer with PIK3CA
mutations. Interestingly, the genes belonging to the metal ion-
binding category (Table 2) included two families of genes that were
among the most strongly up-regulated in PIK3CA-mutated tumors.
They comprised four genes of cytochrome P450 family 4 (CYP4Z1,
CYP4X1, CYP4B1 and the pseudogene (CYP4Z2P) and two solute
carrier genes (SLC4A4 and SLC40A1). All these genes, with
exception of SLC4A4, are associated with iron ion binding. In
addition to these genes, we found on the top of the list lactoferrin
(LTF), also known to be involved in iron metabolism. Among the
genes encoding zinc ion-binding proteins, three (ANPEP, LIMCH1
and NR2F2) are known to be cancer-related.
Besides NR2F2, five other transcription factors, all known to be
involved in tumorigenesis, were identified (Table 2): (a) TFAP2B,a
tumor suppressor gene in breast cancer [12], (b) SEC14L2, a gene
possibly involved in the antiproliferative effect of vitamin E in
cancer [13], (c) ID4, which has been proposed to be involved in
breast cancer, inhibiting mammary epithelial cell differentiation
and stimulating mammary epithelial cell growth [14], (d) TCF7L2,
also named TCF4, a cancer-promoting gene involved in the Wnt
signaling pathway [15], and (e) MSX2, a gene implicated in
mammary gland and breast cancer development [16], and which
is also activated by Wnt signaling [17].
These five transcriptional factors (TFAP2B, SEC14L2, ID4,
TCF7L2 and MSX2), as well as ten genes involved in metal ion
binding (CYP4Z1, CYP4X1, CYP4B1, CYP4Z2P, SLC4A4,
SLC40A1, LTF, ANPEP, LIMCH1 and NR2F2), were selected for
validation by RT-PCR.
Pathway analysis of differentially expressed genes. By
applying KEGG pathway analysis to the 6124 probes differentially
expressed in PIK3CA-mutated tumors, we identified physiological
pathways directly or indirectly associated with PIK3CA mutations.
The most significantly overrepresented pathways are shown in
Table 1. In addition to signaling pathways in cancer cells, the
Table 1. Selected categories significantly over-represented in PIK3CA-mutated breast tumors.
Up- and down-regulated genes Up-regulated genes Down-regulated genes
Gene Category Number of genes P value Number of genes P value Number of genes P value
GENE ONTOLOGY
N Biological Process
Regulation of transcription 581 (14%) 0.0100 282 (17%) ,0.0001 22
Regulation of cell cycle and proliferation 203 (4.8%) 0.0002 94 (5.8%) 0.0004 115 (4.3%) ns
Regulation of cell death 198 (4.7%) 0.0052 84 (5.2%) 0.0360 120 (4.5%) 0.0430
Cell adhesion 171 (4.1%) 0.0073 81 (5.0%) 0.0027 94 (3.5%) ns
Ion transport 169 (4.0%) ns 22 130 (4.9%) 0.0003
Cytoskeleton organization 116 (2.8%) 0.0014 58 (3.6%) 0.0004 63 (2.4%) ns
N Molecular Function
Ion binding 936 (22%) 0.0040 417 (26%) 0.0007 543 (20%) ns
Metal ion binding 920 (15%) 0.0019 411 (25%) 0.0003 533 (20%) ns
Zinc ion binding 518 (22%) 0.0140 268 (16%) ,0.0001 269 (10%) ns
ATP binding 339 (8.1%) 0.0130 130 (8.0%) ns 218 (8.2%) 0.0048
RNA binding 182 (4.4%) 0.0009 87 (5.3%) 0.0008 108 (4.0%) 0.0260
Acetylation 22 22 378 (14%) 0.0004
KEGG PATHWAY
Pathways in cancer 100 (2.4%) ,0.0001 55 (3.4%) ,0.0001 47 (1.1%) ns
MAPK signaling pathway 76 (1.8%) 0.0011 32 (2.0%) 0.0200 47 (1.1%) 0.0190
Calcium signaling pathway 50 (1.2%) 0.0093 10 (0.6%) ns 44 (1.0%) ,0.0001
Jak-STAT signaling pathway 43 (1.0%) 0.0210 17 (1.0%) ns 28 (0.7%) 0.0470
Wnt signaling pathway 41 (1.0%) 0.0370 24 (1.5%) 0.0015 17 (0.4%) ns
Apoptosis 27 (0.6%) 0.0130 12 (0.7%) ns 15 (0.4%) ns
ns: not significant.
The biological processes, molecular functions and physiological pathways of genes were obtained from the DAVID database using GOTERM_BP_FAT, GOTERM_MF_FAT
and KEGG PATHWAY, respectively. The two first tools (Gene Ontology) annotated 4202 genes (1630 up- and 2672 down-regulated genes) while KEGG annotated 960
genes (385 up- and 601 down-regulated genes). The gene enrichment of a given class was measured by determining the number of genes belonging to the classi nt h e
list of significantly altered genes, weighed against the total human genome, and was tested using Fisher exact probability test. Not all significant categories are included
here in order to reduce redundancy. A given gene can belong to several processes.
doi:10.1371/journal.pone.0015647.t001
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Calcium, Jak-STAT, Wnt and apoptosis. The Calcium signaling
pathway was specifically altered by the down-regulated genes,
whereas the Wnt signaling pathway was specifically altered by the
up-regulated genes. The same method applied to the 216 probes
(153 unique genes) that were up-regulated with FC$2 also
revealed the Wnt signaling pathway (P=0.015) (data not shown),
highlighting the importance of this pathway in PIK3CA-mutated
tumors. Five major genes of the Wnt signaling were thus
recognized among the 216 probes (Table S2): MSX2 and
TCF7L2 (already cited), and WNT5A, VANGL2 and
TNFRSF11B/osteoprotegerin. These genes were also selected for
RT-PCR validation.
Finally, among the genes up-regulated with FC$2 (Table S2),
we identified PIK3R1, the gene encoding the PI3K regulatory
subunit, and two other genes of interest: HMGCS2, a nuclear gene
encoding a mitochondrial matrix enzyme involved in ketogenesis
and cholesterol synthesis, processes possibly implicated in the
etiology or progression of breast cancer [18] and MAPT, a protein
enhancing microtubule assembly and stability, that might be
involved in taxane resistance [19]. These three genes were added
to the RT-PCR validation set.
Two-class prediction analysis of differentially expressed
genes. Two-class prediction analysis with the PAM algorithm
was used to identify the group of genes that best characterized
PIK3CA-mutated and wild-type tumors and that classified the
tumors with the smallest number of predictive features. A
threshold of 2.81, that minimized the error, identified 56
differentially expressed probes corresponding to 39 unique genes
(Table S4). Thirty-eight of these 39 unique genes were over-
expressed in ERa-positive breast tumors with PIK3CA mutations,
16 being up-regulated at least 3-fold, while only one gene
(NKAIN1, encoding Na+/K+ ATPase interacting protein) was
down-regulated, with a FC of 3.52. Interestingly, two major genes
involved in the Wnt signaling pathway were also identified by
PAM, namely WNT5A (the most predictive gene) and TCF7L2,
further confirming the importance of this pathway in PIK3CA-
mutated tumors. The previously selected up-regulated genes were
almost all included in the list of the most predictive genes.
PAM analysis identified five interesting new genes that were
Figure 1. Molecular function classifications of genes up-regulated with a FC$2 in the PIK3CA-mutated tumors. Molecular functions
were attributed to 107 of the 153 genes using GOTERM_MF_FAT from the DAVID database. Categories with at least three genes are represented in A.
Subclassification of the 36 genes belonging to the metal ion-binding category is shown in B. All categories were represented and several genes were
common to more than one category. Genes belonging to the metal ion-binding and transcription activity categories are listed in Table 2.
doi:10.1371/journal.pone.0015647.g001
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Probe set FC P value Gene symbol Probe set FC P value Gene symbol
METAL ION BINDING 221584_s_at 2.11 0.0023 KCNMA1
Iron ion binding 1564241_at 2.07 0.0257 ATP1A4
202018_s_at* 10.52 0.0005 LTF 230364_at 2.00 0.0217 CHPT1
237395_at* 7.76 0.0035 CYP4Z1 Sodium ion binding
227702_at* 5.57 0.0032 CYP4X1 203908_at* 4.81 0.0005 SLC4A4
239723_at* 4.42 0.0005 SLC40A1 201242_s_at 2.76 0.0001 ATP1B1
210096_at* 4.12 0.0011 CYP4B1 201243_s_at 2.71 0.0002 ATP1B1
1553434_at* 3.80 0.0009 CYP4Z2P 210738_s_at* 2.13 0.0023 SLC4A4
225871_at 2.34 0.0188 STEAP2 211494_s_at* 2.13 0.0025 SLC4A4
1555497_a_at* 2.34 0.0061 CYP4B1 Potassium ion binding
233123_at* 2.29 0.0139 SLC40A1 244623_at 2.30 0.0152 KCNQ5
223044_at* 2.26 0.0066 SLC40A1 221584_s_at 2.11 0.0023 KCNMA1
205542_at 2.17 0.0266 STEAP1 1564241_at 2.07 0.0257 ATP1A4
219232_s_at 2.15 0.0006 EGLN3 Cobalt ion binding
222453_at 2.14 0.0119 CYBRD1 205513_at 2.87 0.0009 TCN1
204446_s_at 2.19 0.0003 ALOX5 Manganese ion binding
224996_at 2.10 0.0135 ASPH 230364_at 2.00 0.0217 CHPT1
Zinc ion binding
202888_s_at* 3.52 0.0008 ANPEP TRANSCRIPTION REGULATION
212774_at 2.97 0.0320 ZNF238 214451_at* 6.68 0.0020 TFAP2B
212325_at* 2.96 0.0002 LIMCH1 1553394_a_at* 4.34 0.0035 TFAP2B
225728-at 2.72 0.0141 SORBS2 223864_at 4.25 0.0399 ANKRD30A
207981_s_at 2.69 0.0213 ESRRG 230316_at* 3.05 0.0006 SEC14L2
212328_at* 2.69 0.0001 LIMCH1 204541_at* 3.03 0.0004 SEC14L2
204288_s_at 2.69 0.0073 SORBS2 209292_at* 3.03 0.0002 ID4
212327_at* 2.49 0.0008 LIMCH1 212774_at 2.97 0.0320 ZNF238
241459_at* 2.35 0.0003 LIMCH1 209291_at* 2.96 0.0001 ID4
227811_at 2.20 0.0051 FGD3 207981_s_at 2.69 0.0213 ESRRG
211965_at 2.18 0.0002 ZFP36L1 226847_at 2.61 0.0020 FST
215073_s_at* 2.08 0.0063 NR2F2 243030_at 2.49 0.0006 MAP3K1
231929_at 2.07 0.0039 IKZF2 226992_at 2.23 0.0064 NOSTRIN
214761_at 2.05 0.0016 ZNF423 212762_s_at* 2.18 0.0000 TCF7L2
Calcium ion binding 210319_x_at* 2.17 0.0011 MSX2
219197_s_at 3.08 0.0173 SCUBE2 216511_s_at* 2.16 0.0000 TCF7L2
204455_at 2.70 0.0065 DST 224975_at 2.13 0.0003 NFIA
229030_at 2.42 0.0370 CAPN8 240024_at* 2.12 0.0016 SEC14L2
209369_at 2.42 0.0174 ANXA3 209706_at 2.12 0.0292 NKX361
203887_s_at 2.20 0.0006 THBD 221666_s_at 2.09 0.0050 PYCARD
204446_s_at 2.19 0.0003 ALOX5 215073_s_at* 2.08 0.0063 NR2F2
224996_at 2.10 0.0135 ASPH 216035_x_at* 2.08 0.0000 TCF7L2
221584_s_at 2.11 0.0023 KCNMA1 231929_at 2.07 0.0039 IKZF2
1564241_at 2.07 0.0257 ATP1A4 214761_at 2.05 0.0016 ZNF423
Magnesium ion binding 220625_s_at 2.02 0.0286 ELF5
227556_at 2.99 0.0007 NME7 226806_s_at 2.02 0.0006 NFIA
243030_at 2.49 0.0006 MAP3K1
These genes are ranked according to the fold change (FC) in tumors with PIK3CA mutations relative to non mutated tumors. Several genes were common to more than
one category. The genes marked with an asterisk were selected for RT-PCR validation.
doi:10.1371/journal.pone.0015647.t002
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and NRIP3, which were added to the RT-PCR validation set.
Among the down-regulated genes, NKAIN1 was selected for RT-
PCR validation, along with two other genes known to be involved
in cancer biology: TUSC3 and TPD52, that were among the 28
most strongly down-regulated probes (FC$2) (Table S3) and that
were also among the most predictive genes in PAM analysis with a
lower FC threshold of 2.5 (data not shown).
Combined analysis of the GO, KEGG and PAM approaches
identified 29 most promising genes (26 up-regulated and 3 down-
regulated) for RT-PCR validation. The expression status of these
genes was first confirmed in the same series of 43 breast tumors
(Table 3). Strong positive correlations were observed between the
microarray and RT-PCR expression levels of each gene (Spear-
man’s correlation coefficients ranged from 0.69 to 0.97 and were
all significant, at P,0.0001; data not shown).
mRNA expression of the 29 genes of interest in 249 ERa-
positive breast tumors
Overall expression of the 29 differentially expressed
genes. The expression levels of the 29 genes selected by
microarray analysis were then verified by RT-PCR in a large
independent cohort of 249 ERa-positive breast tumors, of which
157 were PIK3CA wild-type and 92 were PIK3CA-mutated (Table
S1). This PIK3CA mutation frequency of 37% was in keeping with
the results of previous studies showing a mutation rate of up to
40% in ERa-positive breast tumors [7,8]. Almost all the tumors
had a single mutation, 44 (47.8%) in exon 9 (helical domain) and
46 (50%) in exon 20 (kinase domain) [7]. Two tumors (2.2%)
carried two mutations, located in exons 9 and 20 in one case, and
in exon 20 in the second case.
Nineteen (66%) of the 29 selected genes showed significantly
different expression between mutated and wild-type tumors in the
Table 3. Microarray and RT-PCR analyses of the 29 genes in 43 ERa-positive breast tumors.
Microarray analysis RT-PCR analysis
Symbol Gene GenBank FC P value
PIK3CA non mutated
(n=29)
PIK3CA mutated
(n=14) FC P value
UP-REGULATED GENES
ANPEP* NM_001150 3.52 0.0008 0.17 (0.03–1.52) 0.37 (0.10–23.7) 2.16 0.0033
CYP4B1* NM_000779 4.12 0.0011 3.13 (0.11–71.5) 10.6 (2.14–431) 3.40 0.0033
CYP4X1 NM_178033 5.57 0.0032 1.04 (0.05–73.3) 5.85 (0.63–97.7) 5.62 0.0124
CYP4Z1 NM_171834 7.76 0.0035 0.36 (0.01–220) 9.17 (0.10–311) 25.15 0.0085
CYP4Z2P* NR_002788 3.80 0.0009 34.8 (0.12–1457) 160 (22.9–2103) 4.59 0.0007
HMGCS2* NM_005518 5.31 0.0003 0.10 (0.00–11.1) 3.40 (0.07–16.3) 32.56 0.0011
ID4* NM_001546 3.03 0.0002 0.07 (0.02–0.61) 0.16 (0.05–1.03) 2.13 0.0133
LIMCH1* NM_014988 2.96 0.0002 0.54 (0.10–3.83) 1.66 (0.48–2.87) 3.06 0.0014
LTF* NM_002343 10.52 0.0005 0.03 (0.00–11.3) 0.86 (0.00–37.4) 31.54 0.0012
MAPT* NM_016835 2.82 0.0004 1.09 (0.02–12.1) 4.40 (0.04–10.2) 4.02 0.0010
MSX2 NM_002449 2.17 0.0011 1.74 (0.09–4.56) 3.32 (1.56–8.57) 1.91 0.0025
NR2F2 NM_021005 2.08 0.0063 0.51 (0.14–2.02) 1.06 (0.58–2.20) 2.09 0.0009
NRIP3* NM_020645 3.28 0.0002 0.94 (0.05–18.9) 3.64 (0.64–33.9) 3.87 0.0025
NTN4* NM_021229 4.21 0.0008 0.48 (0.05–3.07) 1.87 (0.68–3.19) 3.91 0.0004
PIK3R1* NM_181523 2.45 ,0.0001 0.28 (0.07–0.89) 0.49 (0.18–1.61) 1.74 0.0053
REEP1* NM_022912 3.30 0.0005 1.15 (0.16–14.4) 3.49 (1.36–8.99) 3.04 0.0446
SEC14L2* NM_012429 3.03 0.0006 0.98 (0.13–16.1) 5.54 (0.37–24.4) 5.68 0.0049
SLC4A4* NM_003759 4.81 0.0005 0.28 (0.10–8.45) 3.45 (0.00–116) 12.15 0.0190
SLC40A1* NM_014585 4.42 0.0005 0.37 (0.11–7.79) 1.14 (0.26–6.62) 3.12 0.0068
TCF7L2 NM_030756 2.08 ,0.0001 0.24 (0.00–0.64) 0.35 (0.23–0.91) 1.45 0.0010
TFAP2B* NM_003221 6.68 0.0020 0.09 (0.00–26.0) 1.32 (0.00–34.7) 15.23 0.0164
TMC5* NM_024780 4.27 0.0022 2.53 (0.05–36.4) 9.45 (1.26–37.8) 3.74 0.0177
TNFRSF11B NM_002546 2.12 0.0023 0.67 (0.13–10.6) 2.64 (0.44–31.3) 3.91 0.0004
VANGL2 NM_020335 2.49 0.0009 0.64 (0.03–3.44) 1.90 (0.13–5.37) 2.99 0.0018
VTCN1* NM_024626 5.47 0.0007 0.19 (0.00–4.89) 1.12 (0.22–23.3) 5.97 0.0025
WNT5A* NM_003392 3.43 ,0.0001 0.56 (0.05–6.03) 2.10 (0.37–6.17) 3.75 0.0013
DOWN-REGULATED GENES
NKAIN1* NM_024522 23.52 0.0006 137.8 (0.94–560) 12.13 (1.39–389) 211.36 0.0124
TPD52 NM_005079 22.17 0.0014 6.29 (3.13–81.8) 3.88 (1.20–11.68) 21.62 0.0020
TUSC3 NM_006765 22.48 0.0026 0.58 (0.09–9.35) 0.32 (0.12–0.63) 21.83 0.0092
For each gene, we report the fold change (FC) between tumors with and without PIK3CA mutations. RT-PCR results are expressed as the median (range) mRNA level for
each gene relative to normal breast tissues. Genes identified by PAM analysis are marked with an asterisk.
doi:10.1371/journal.pone.0015647.t003
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the screening cohort (Table 4). Among the three down-regulated
genes of interest in the screening set, only NKAIN1 was significantly
down-regulated in the validation set. Among the 26 up-regulated
genes, 18 were also up-regulated in the validation set. With
exception of VANGL2, up-regulation of the genes involved in Wnt
signaling pathway, namely WNT5A, MSX2, TCF7L2 and
TNFRSF11B, was confirmed in the validation set, further
emphasizing the important role of the Wnt signaling pathway in
PIK3CA-mutated breast cancer. Up-regulation was also confirmed
for genes related to breast cancer (MAPT, HMGCS2, NR2F2 and
TFAP2B), genes involved in metal ion binding (CYP4Z1, CYP4Z2P,
SLC40A1, LTF and LIMCH1) and also NRIP3, NTN4, REEP1,
SEC14L2 and TMC5. Deregulation of these genes was not related
to ERa status or proliferation since similar expression levels of
ERa and MKI67 were observed in PIK3CA-mutated and -non
mutated tumors (Table 4). Only 2 of the 29 selected genes showed
significantly different expression between PIK3CA exon 9- and
exon 20-mutated tumors, namely TFAP2B and NRIP3 (Table S5).
Interestingly, TFAP2B was over-expressed in exon 20-mutated
tumors and NRIP3 in exon 9-mutated tumors.
Identification of the most discriminatory genes. PAM
prediction analysis was then used to test the ability of each gene to
classify the 249 ERa-positive breast tumors according to PIK3CA
mutation status. NKAIN1 was the most predictive gene (PAM rank)
(Table 4). NKAIN1 was also an essential classifier in supervised
Table 4. Relative mRNA expression levels of the 29 genes in 249 ERa-positive breast tumors.
Symbol Gene GenBank
PIK3CA non mutated
(n=157)
PIK3CA mutated
(n=92) FC P value Rank in PAM
UP-REGULATED GENES
ANPEP NM_001150 0.46 (0.00–154) 0.39 (0.06–18.3) 20.84 ns 15
CYP4B1 NM_000779 6.59 (0.00–222) 5.72 (0.00–178) 21.12 ns 20
CYP4X1 NM_178033 2.34 (0.02–59) 3.78 (0.05–101) 1.62 ns 11
CYP4Z1 NM_171834 1.15 (0.01–140) 2.97 (0.01–254) 2.58 0.0134 4
CYP4Z2P NR_002788 38.3 (0.00–1815) 66.4 (0.00–1069) 1.74 0.0060 8
HMGCS2 NM_005518 0.29 (0.00–24.8) 0.60 (0.00–25.7) 2.09 0.0487 10
ID4 NM_001546 0.13 (0.00–9.10) 0.17 (0.02–9.57) 1.30 ns 28
LIMCH1 NM_014988 0.73 (0.05–6.59) 1.09 (0.08–8.58) 1.49 0.0007 19
LTF NM_002343 0.08 (0.00–14.7) 0.14 (0.00–41.8) 1.74 0.0036 7
MAPT NM_016835 3.03 (0.07–71.1) 4.52 (0.15–26.2) 1.49 0.0039 14
MSX2 NM_002449 2.26 (0.00–13.9) 3.69 (0.11–39.3) 1.63 0.0003 5
NR2F2 NM_021005 0.79 (0.06–10.8) 1.00 (0.11–7.27) 1.25 0.0415 24
NRIP3 NM_020645 1.55 (0.00–168) 2.69 (0.10–105) 1.73 0.0250 16
NTN4 NM_021229 0.75 (0.03–5.47) 1.17 (0.04–10.2) 1.57 0.0002 12
PIK3R1 NM_181523 0.32 (0.06–1.38) 0.37 (0.08–1.30) 1.16 ns 27
REEP1 NM_022912 1.85 (0.00–12.1) 2.59 (0.19–21.8) 1.40 0.0053 6
SEC14L2 NM_012429 2.49 (0.00–24.0) 4.51 (0.16–39.1) 1.81 ,0.0001 2
SLC4A4 NM_003759 0.29 (0.00–178) 0.42 (0.00–128) 1.43 ns 17
SLC40A1 NM_014585 0.88 (0.03–7.81) 1.22 (0.00–17.9) 1.38 0.0311 13
TCF7L2 NM_030756 0.26 (0.03–1.05) 0.32 (0.06–1.26) 1.21 0.0373 26
TFAP2B NM_003221 1.28 (0.00–35.7) 5.53 (0.00–179) 4.31 0.0055 3
TMC5 NM_024780 4.79 (0.01–69.0) 5.77 (0.11–46.2) 1.20 0.0331 9
TNFRSF11B NM_002546 1.25 (0.00–50.3) 1.90 (0.15–21.8) 1.52 0.0068 21
VANGL2 NM_020335 0.73 (0.03–4.64) 0.82 (0.07–9.09) 1.12 ns 23
VTCN1 NM_024626 0.61 (0.00–10.3) 0.64 (0.01–15.4) 1.05 ns 22
WNT5A NM_003392 0.74 (0.03–12.4) 1.17 (0.18–7.27) 1.59 ,0.0001 18
DOWN-REGULATED GENES
NKAIN1 NM_024522 81.1 (0.54–1648) 57.7 (0.71–560) 21.41 0.0471 1
TPD52 NM_005079 6.01 (1.30–115) 5.34 (1.75–80.9) 21.12 ns 25
TUSC3 NM_006765 0.68 (0.08–3.72) 0.63 (0.08–6.31) 21.09 ns 29
CONTROL GENES
ERa NM_000125 8.77 (1.27–68.9) 8.86 (1.59–39.8) 1.01 ns 2
MKI67 NM_002417 12.1 (0.86–57.2) 11.0 (1.79–313) 0.91 ns 2
ns: not significant.
Results are expressed as the median (range) mRNA level for each gene relative to normal breast tissues. For each gene, we report the fold change (FC) between tumors
with and without PIK3CA mutations and the PAM rank.
doi:10.1371/journal.pone.0015647.t004
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NKAIN1 classified the 249 breast tumors significantly more
accurately than the set of 18 up-regulated genes without
NKAIN1 (accuracy 59% and 57%, X
2 test P values of 0.0006
and 0.0141, respectively) (Table S6). Three different minimal sets
of 4, 5 and 6 genes, all including both NKAIN1 and CYP4Z2P,
showed the same overall clustering accuracy of 59.4% (Table S6).
However, the 5-gene group (NKAIN1-CYP4Z2P-NRIP3-SEC14L2-
TFAP2B) had the most significant discriminatory value
(MCC=0.2334, P=0.0002) correctly clustering 66 of the 92
mutated tumors and 82 of the 157 non mutated tumors. Notably,
this 5-gene set contained the two genes that were differently
expressed between exon 9- and exon 20-mutated tumors, and thus
had the best capacity to distinguish between these two tumor
categories (data not shown). The other two gene sets, both
comprising genes involved in Wnt signaling (NKAIN1-CYP4Z2P-
WNT5A-TMC5 and NKAIN1-CYP4Z2P-WNT5A-MAPT-MSX2-
TFAP2B), classified 65 mutated and 83 non mutated tumors
correctly (MCC=0.2286, P=0.0003).
Discussion
We used a two-step strategy to identify downstream target genes
and signaling pathways affected by PIK3CA mutations in breast
tumors. We first applied a pangenomic oligonucleotide microarray
approach to a series of 43 ERa-positive tumors with and without
PIK3CA mutations, and then validated genes of interest by RT-
PCR in an independent series of 249 ERa-positive tumors. A
robust set of 19 genes differentially expressed in PIK3CA-mutated
and wild-type tumors was thus identified.
Over-expression of several genes involved in Wnt signaling
(WNT5A, TCF7L2, MSX2 and TNFRSF11B), regulation of gene
transcription (SEC14L2, MSX2, TFAP2B and NRIP3) and metal
ion binding (CYP4Z1, CYP4Z2P, SLC40A1, LTF and LIMCH1) was
observed in PIK3CA-mutated tumors. Several of these genes have
been linked to breast cancer (MAPT, HMGCS2, NR2F2, TFAP2B,
NTN4, SEC14L2 and LTF).
The human Wnt signaling network is important for regulation
of proliferation, differentiation, growth and survival from the
embryo stage [20,21]. Crosstalk of complex pathways belonging to
Wnt signaling has been observed leading to, when altered,
disparate effects in different tumor types [22-24]. We observed
over-expression of four major genes involved in the Wnt pathway,
namely WNT5A, TCF7L2, MSX2 and TNFRSF11B. WNT5A
encodes a major Wnt ligand affecting tumor cell motility and
metastasis, but its role in breast cancer is controversial [23]. The
emerging view is that, in breast cancer, WNT5A has a suppressive
effect, inhibiting migration and invasion of breast cancer cell lines
[24]. Moreover, WNT5A over-expression observed in invasive
breast tumors has been associated with a favorable outcome [24].
PIK3CA mutations have also been associated with favorable
outcome of breast cancer patients [1,3,4,25]. We can thus suggest
a link between gain-of-function mutation in PIK3CA, up-regulation
of WNT5A and favorable outcome in breast cancer. We also
observed over-expression of TCF7L2, which encodes one of the
four major transcription factors involved in the Wnt signaling
pathway [20,26], as well as two other genes (MSX2 and
TNFRSF11B) known to be downstream targets of the Wnt
signaling pathway [27–29]. Wnt signaling has a major role in
cancer stem cell self-renewal and tumor maintenance [20,30] and
contributes to tumor invasion, metastasis and angiogenesis [31].
Recent studies have identified a role of Wnt pathway in epidermal-
mesenchymal transition during breast cancer development
[32,33]. Thus, Wnt pathway activation appears to be an important
consequence of PIK3CA mutations in breast tumors, in keeping
with recently observed crosstalk between the PI3K/Akt and Wnt
pathways in both physiological (myeloid progenitor cells) [21] and
pathological conditions (medulloblastoma) [34].
Better understanding of the biological functions of the Wnt and
PI3K/Akt pathways and their interplay could have therapeutic
implications for breast cancer. Drugs targeting the PI3K/Akt
pathway have given promising preliminary results in human
malignancies [35,36]. However, as the PI3K pathway is crucial for
metabolic processes, PI3K inhibitors might also have side effects,
especially affecting insulin signaling and cardiac functions [36,37].
In contrast, targeting of downstream Wnt signaling events might
have fewer adverse effects, considering their crucial importance in
embryonic development [23,38].
Genes encoding metal ion-binding proteins were also over-
expressed in PIK3CA-mutated tumors. Such metal ion-binding
proteins have regulatory roles in central cellular processes such as
gene expression, proliferation, differentiation and survival. In-
creased expression of these proteins in ERa-positive breast tumors
has also been reported by Abba et al. [39]. We observed over-
expression of LIMCH1, a gene encoding zinc-binding protein, and
also four genes encoding iron-binding proteins (LTF, SLC40A1,
CYP4Z1 and CYP4Z2P) previously linked to breast cancer. LTF
encodes lactoferrin, a protein involved in non specific immunity
and that may inhibit carcinogenesis and tumor growth [40].
CYP4Z1 and its pseudogene CYP4Z2P are two members of
cytochrome P450 family 4 which have been found to be over-
expressed in about 50% of breast cancers relative to normal breast
tissue from the same patients [41]. Here, we confirm that the
pseudogene CYP4Z2P is expressed in both PIK3CA-mutated and -
non mutated ERa-positive breast tumors, by using specific primers
unambiguously distinguishing CYP4Z2P from CYP4Z1. Thus,
CYP4Z2P is transcriptionally active, but its translation remains to
be studied. CYP4Z2P is located in a head-to-head orientation close
to CYP4Z1 in chromosome region 1p33 [41], raising the possibility
that expression of these two genes is co-regulated in PIK3CA-
mutated breast tumors.
We identified several genes previously implicated in breast
cancer development or outcome. The proteins encoded by
TFAP2B, NTN4 and SEC14L2 have been linked to tumors with
less aggressive features and better outcome [12,13,42]. MAPT has
been proposed as a predictive marker of taxane responsiveness in
breast cancer [43]. NR2F2 has been also detected up-regulated in
breast cancer, but its involvement in tumor development remains
elusive because of its ability to affect both pro-oncogenic and anti-
oncogenic proteins [44,45]. HMGCS2 was recently shown to be
regulated in response to hormonal stimulation [18].
NRIP3, TMC5, REEP1 and NKAIN1, whose expression had not
previously been described in breast cancer, were also deregulated
in the PIK3CA-mutated breast tumors. NRIP3, TMC5 and REEP1
are differentially expressed in various other tumor types [46–48].
Interestingly, NKAIN1 was the only gene under-expressed in
PIK3CA-mutated tumors and was also the most discriminatory
gene for these tumors. The role of these genes in breast cancer
development remains to be evaluated in following studies.
Recently, Loi et al. identified a 278 gene-expression signature
associated specifically with PIK3CA exon 20-mutated ER-positive/
ERBB2-negative tumors [25]. These authors observed an
unexpected significant down-expression of some Akt-regulated
genes such as RPS6KB1 in their PIK3CA-mutated tumor series, but
a normal level of AKT1 and mTOR transcripts. They also showed
that phosphor-Akt expression was not significantly up-regulated at
the protein level. In the present study, we did not identify
RPS6KB1, AKT1 and mTOR in our final 19-gene set nor in the list
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(Table S2 and S3). Interestingly, among the 168 significantly up-
regulated genes detected by Loi et al., WNT5A and MSX2, as well
as HMGCS2 and LTF, were identified in agreement with our
results. The data of Loi et al. [25] confirm thus the positive
association between PIK3CA mutation and Wnt signaling pathway
activation reported in the present manuscript.
In conclusion, this gene expression profiling study suggests that
over-expression of genes belonging to the Wnt signaling pathway
may play a pivotal role in PIK3CA-mutated breast tumors, in
particular WNT5A. Further studies of biological mechanisms
affected by PIK3CA mutations may have therapeutic implications.
Supporting Information
Table S1 Molecular, pathological and clinical charac-
teristics of patients in relation to metastasis free
survival (MFS) in the 43 ERa-positive and 249 ERa-
positive patient series.
(PDF)
Table S2 2538 probes up-regulated in tumors with
PIK3CA mutations (Mutated) compared to tumors
without PIK3CA mutation (Normal) with a P value
,0.05 identified by a parametric t test using BRB
ArrayTools. These genes were ranked according to fold change
(FC) calculated between expression intensities of tumors with
PIK3CA mutations and those of tumors without PIK3CA mutation.
The 216 probes with a FC$2 are put in bold. In this list, the
probes belonging to Wnt signaling pathway are shaded in light
grey, and PIK3R1, HMGCS2 and MAPT are shaded in dark grey.
(PDF)
Table S3 3586 probes down-regulated in tumors with
PIK3CA mutations (Mutated) compared to tumors
without PIK3CA mutation (Normal) with a P value
,0.05 identified by a parametric t test using BRB
ArrayTools. These genes were ranked according to fold change
(FC) calculated between expression intensities of tumors with
PIK3CA mutations and those of tumors without PIK3CA mutation.
The 28 probes with a FC$2 are put in bold.
(PDF)
Table S4 List of 56 probes (39 unique genes) deregulat-
ed in REa-positive breast tumors with PIK3CA muta-
tions compared to those without PIK3CA mutation
identified by PAM. These genes are presented according to
the rank in PAM output. For each gene, we report the fold change
(FC) calculated between expression intensities of tumors with and
without PIK3CA mutations using BRB Arrays Tools. The genes
with a FC$3 are put in bold.
(PDF)
Table S5 Relative mRNA expression levels of the 29
genes in the 44 ERa-positive breast tumors with exon 9
PIK3CA mutations compared to the 47 tumors with exon
20 PIK3CA mutations. The tumor with PIK3CA mutations in
both exon 9 and exon 20 was excluded from the analysis. For each
gene, we report the median (range) of the mRNA levels of each
gene relative to normal breast tissue samples, the fold change (FC)
between tumors with exon 9-mutated and exon 20-mutated
PIK3CA and the P value associated to Mann-Whitney U test.
(PDF)
Table S6 Supervised hierarchical clustering analysis of
the 249 ERa-positive breast tumors. Classification perfor-
mance of discriminating gene sets identified from the 19
significantly deregulated genes in tumors with PIK3CA mutations
(18 up-regulated genes + NKAIN1). Each gene set separates the 157
tumors without PIK3CA mutation (N) and the 92 tumors with
PIK3CA mutations (M) in two main clusters (cluster 1 and 2).
(PDF)
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